<div id="readability-page-1"><p>Congress Asset Management Co. trimmed its stake in shares of  Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 96.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,501 shares of the company's stock after selling 359,846 shares during the quarter. Congress Asset Management Co.'s holdings in Inspire Medical Systems were worth $1,002,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li></ul><p>Other hedge funds and other institutional investors also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its position in shares of  Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company's stock valued at $8,190,000 after acquiring an additional 18,857 shares during the period.  Texas Permanent School Fund Corp grew its holdings in  Inspire Medical Systems by 42.2% in the second quarter. Texas Permanent School Fund Corp now owns 40,042 shares of the company's stock worth $5,196,000 after purchasing an additional 11,892 shares during the period.  Nordea Investment Management AB bought a new stake in  Inspire Medical Systems in the second quarter valued at $1,634,000.  Bayforest Capital Ltd increased its stake in  Inspire Medical Systems by 2,465.9% in the first quarter. Bayforest Capital Ltd now owns 5,491 shares of the company's stock valued at $875,000 after purchasing an additional 5,277 shares in the last quarter.  Finally, CW Advisors LLC raised its holdings in shares of  Inspire Medical Systems by 45.3% during the second quarter. CW Advisors LLC now owns 49,960 shares of the company's stock valued at $6,484,000 after purchasing an additional 15,576 shares during the period. 94.91% of the stock is owned by institutional investors and hedge funds. </p><h2>Inspire Medical Systems Stock Performance</h2><p>Shares of INSP opened at $97.70 on Tuesday. The firm has a market capitalization of $2.84 billion, a P/E ratio of 66.46, a P/E/G ratio of 11.12 and a beta of 0.69. Inspire Medical Systems, Inc. has a 52 week low of $70.77 and a 52 week high of $216.01. The stock has a 50 day moving average price of $99.98 and a two-hundred day moving average price of $102.96. </p><ul><li>Inspire Medical Up 15% After Breakout, Analysts Say It's A Buy</li></ul><p>Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.53. The company had revenue of $224.50 million for the quarter, compared to analysts' expectations of $220.39 million. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.Inspire Medical Systems's quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.60 earnings per share.  On average, equities analysts forecast that  Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year. </p><h2>Analyst Ratings Changes</h2><p>Several brokerages have recently commented on INSP. Mizuho raised their target price on Inspire Medical Systems from $110.00 to $130.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 17th. Truist Financial upgraded Inspire Medical Systems from a &#34;hold&#34; rating to a &#34;buy&#34; rating and increased their price target for the stock from $128.00 to $165.00 in a report on Wednesday, November 26th. Stifel Nicolaus  set a $110.00 price objective on Inspire Medical Systems and gave the company a &#34;buy&#34; rating in a report on Monday, November 24th. Weiss Ratings  reaffirmed a &#34;sell (d+)&#34; rating on shares of Inspire Medical Systems in a research report on Wednesday, December 10th. Finally, Wells Fargo &amp; Company upgraded Inspire Medical Systems from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating and cut their target price for the stock from $101.00 to $90.00 in a report on Tuesday, November 4th. Eleven analysts have rated the stock with a Buy rating, seven have issued  a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat.com, the company  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $138.88.</p><ul><li>Are Small Caps a Harbinger of Market Declines?</li></ul><p><b>Read Our Latest Research Report on Inspire Medical Systems</b></p><h2>Insider Activity</h2><p>In other news, Director Shawn Mccormick sold 2,000 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the completion of the sale, the director owned 26,046 shares in the company, valued at $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.30% of the stock is currently owned by insiders. </p><h2>Inspire Medical Systems News Summary</h2><p>Here are the key news stories impacting Inspire Medical Systems this week:</p><ul>   <li><span>Positive Sentiment: </span>Zacks published a bullish note arguing INSP remains worth holding due to strong Inspire V clinical data, improving reimbursement visibility and cost control despite inventory and GLP‑1 headwinds. <i></i><span>Zacks: Retain INSP Stock</span></li>    <li><span>Positive Sentiment: </span>An analyst price‑target increase was reported (MSN coverage of a 12.65% raise to $144.32), signaling some sell‑side conviction on upside after recent weakness. <i></i><span>MSN: Price Target Increase</span></li>    <li><span>Negative Sentiment: </span>Multiple securities class actions and investor notices were filed or announced today, alleging disclosure failures tied to product delays, Medicare billing software issues and an Inspire V inventory glut; dozens of plaintiff firms are soliciting lead‑plaintiff motions with a January 5, 2026 deadline — this increases legal exposure, potential settlements and short‑term share pressure. <i></i><span>BLB&amp;G Filing</span> <i></i><span>Rosen Notice</span> <i></i><span>Hagens Berman Alert</span></li>    <li><span>Negative Sentiment: </span>Numerous additional plaintiff firms (BFA Law, Glancy Prongay &amp; Murray, The Gross Law Firm, Faruqi &amp; Faruqi, Schall, Bronstein Gewirtz, etc.) issued reminders encouraging investors to seek lead‑plaintiff roles — the flurry of notices amplifies headline risk and could prolong volatility as the litigation unfolds. <i></i><span>MarketWatch / BFA</span> <i></i><span>Glancy Notice</span></li> </ul><h2>About Inspire Medical Systems</h2> (Free Report)<p>Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.  </p><p>The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.</p><h2>See Also</h2><ul><li>Five stocks we like better than Inspire Medical Systems</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>The Last Gold Bull Market </li></ul><p><strong>Want to see what other hedge funds are holding INSP?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSP - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUlOU1A"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Inspire Medical Systems Right Now?</h2><p>Before you consider Inspire Medical Systems, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inspire Medical Systems wasn't on the list.</p><p>While Inspire Medical Systems currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

INSP

<p>Congress Asset Management Co. significantly reduced its stake in Inspire Medical Systems by 96.4% in Q3, now holding $1 million in shares. Other institutional investors adjusted their positions, with Goldman Sachs increasing its stake by 57.9%. Inspire Medical's stock performance shows a market cap of $2.84 billion and a recent earnings beat. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a target price of $138.88.</p>

Congress Asset Management Co. Has $1 Million Stock Holdings in Inspire Medical Systems, Inc. $INSP